IMPACT OF COVID-19 ON OUTCOMES OF PATIENTS WITH HEMATOLOGIC MALIGNANCIES: A MULTI-CENTER, RETROSPECTIVE STUDY
Objectives: Patients with hematologic malignancies have a high risk of coronavirus disease 2019 (COVID-19) mortality. This study aimed to investigate the impact of COVID-19 on mortality rates in patients with various hematologic malignancies and to determine risk factors associated with all-cause m...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2022-10-01
|
| Series: | Mediterranean Journal of Hematology and Infectious Diseases |
| Subjects: | |
| Online Access: | http://mjhid.org/index.php/mjhid/article/view/5054 |
| _version_ | 1826954353291821056 |
|---|---|
| author | İbrahim Halil Açar Sebnem Izmir Güner Muzeyyen Aslaner Ak Mesut Gocer Erman Ozturk Figen Atalay Gulden Sincan Aysun Senturk Yikilmaz Omer Ekinci Idris Ince Emine Gulturk Nazli Demir Ali Dogan Yildiz Ipek Birol Guvenc |
| author_facet | İbrahim Halil Açar Sebnem Izmir Güner Muzeyyen Aslaner Ak Mesut Gocer Erman Ozturk Figen Atalay Gulden Sincan Aysun Senturk Yikilmaz Omer Ekinci Idris Ince Emine Gulturk Nazli Demir Ali Dogan Yildiz Ipek Birol Guvenc |
| author_sort | İbrahim Halil Açar |
| collection | DOAJ |
| description |
Objectives: Patients with hematologic malignancies have a high risk of coronavirus disease 2019 (COVID-19) mortality. This study aimed to investigate the impact of COVID-19 on mortality rates in patients with various hematologic malignancies and to determine risk factors associated with all-cause mortality.
Methods: A multi-center, observational retrospective analysis of patients with hematologic malignancies infected with COVID-19 between July 2020 and December 2021 was performed. Demographic data, clinical characteristics, and laboratory parameters were recorded. Patients were grouped as non-survivors and survivors. All-cause mortality was the primary outcome of the study.
Results: There were 569 patients with a median age of 59 years. Non-Hodgkin lymphoma (22.0%) and multiple myelomas (18.1%) were the two most frequent hematologic malignancies. The all-cause mortality rate was 29.3%. The highest mortality rates were seen in patients with acute myeloid leukemia (44.3%), acute lymphoid leukemia (40.5%), and non-Hodgkin lymphoma (36.8%). The non-survivors were significantly older (p<0.001) and had more comorbidities (p<0.05). There were significantly more patients with low lymphocyte percentage (p<0.001), thrombocytopenia (p<0.001), and high CRP (p<0.001) in the non-survived patients. Cardiac comorbidities, (p=0.016), cytotoxic chemotherapy (p=0.024), low lymphocyte percentage (p=0.025), thrombocytopenia (p<0.0001), and high CRP values (p=0.017) were the independent risk factors for the prediction of mortality.
Conclusions: In patients with hematologic malignancies, coexistent COVID-19 leads to a higher mortality rate in elderly patients with more comorbidities. Acute myeloid and lymphoid leukemia and non-Hodgkin lymphoma have the highest mortality rates. Cardiac diseases, cytotoxic chemotherapy, lymphopenia, thrombocytopenia, and high CRP are the independent risk factors for mortality in hematologic malignancy patients with COVID-19.
Keywords: Covid; Hematologic Malignancy; Cytotoxic chemotherapy.
|
| first_indexed | 2024-04-11T08:54:37Z |
| format | Article |
| id | doaj.art-f42b6cab2f704cc7a8eb0e5543b1d408 |
| institution | Directory Open Access Journal |
| issn | 2035-3006 |
| language | English |
| last_indexed | 2025-02-17T23:35:44Z |
| publishDate | 2022-10-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Mediterranean Journal of Hematology and Infectious Diseases |
| spelling | doaj.art-f42b6cab2f704cc7a8eb0e5543b1d4082024-12-02T03:44:11ZengPAGEPress PublicationsMediterranean Journal of Hematology and Infectious Diseases2035-30062022-10-0114110.4084/MJHID.2022.074IMPACT OF COVID-19 ON OUTCOMES OF PATIENTS WITH HEMATOLOGIC MALIGNANCIES: A MULTI-CENTER, RETROSPECTIVE STUDYİbrahim Halil Açar0Sebnem Izmir Güner 1Muzeyyen Aslaner Ak2Mesut Gocer3Erman Ozturk 4Figen Atalay5Gulden Sincan 6Aysun Senturk Yikilmaz7Omer Ekinci8Idris Ince9Emine Gulturk 10Nazli Demir11Ali Dogan12Yildiz Ipek13Birol GuvencAdana Cukurova University, School of Medicine, Hematology Clinicİstanbul Gelisim University, Memorial Sisli Hospital Hematology&Bone Marrow Transplantation UniteZonguldak Bulent Ecevit University, Faculty of Medicine, Hematology Department, Zonguldak, TurkeyHealth Sciences University, Antalya Training and Research Hospital, Hematology Clinic, Antalya, Turkey Istanbul Medeniyet University, Faculty of Medicine, Department of HematologyBaskent University, School of Medicine, Department of Hematology, Ankara, TurkeyAtaturk University, Faculty of Medicine, Department of Hematology, Erzurum, TurkeyDenizli Goverment Hospital, Hematology Clinic, Denizli, TurkeyMedicana International Istanbul, Adult Hematology and Bone Marrow Transplantation Center, Istanbul, TurkeyDr. Ersin Arslan Training and Research Hospital, Department of Hematology, Gaziantep, TurkeyBakirkoy Dr Sadi Konuk Training and Research Hospital, Hematology Clinic, Istanbul, TurkeySisli Hamidiye Etfal Training and Research Hospital, Hematology Clinic, Istanbul, TurkeyVan Yuzuncu Yil University, Faculty of Medicine, Department of Hematology, Van, TurkeyIstanbul Kartal Dr. Lutfi Kirdar City Hospital, Hematology Clinic, Istanbul, Turkey Objectives: Patients with hematologic malignancies have a high risk of coronavirus disease 2019 (COVID-19) mortality. This study aimed to investigate the impact of COVID-19 on mortality rates in patients with various hematologic malignancies and to determine risk factors associated with all-cause mortality. Methods: A multi-center, observational retrospective analysis of patients with hematologic malignancies infected with COVID-19 between July 2020 and December 2021 was performed. Demographic data, clinical characteristics, and laboratory parameters were recorded. Patients were grouped as non-survivors and survivors. All-cause mortality was the primary outcome of the study. Results: There were 569 patients with a median age of 59 years. Non-Hodgkin lymphoma (22.0%) and multiple myelomas (18.1%) were the two most frequent hematologic malignancies. The all-cause mortality rate was 29.3%. The highest mortality rates were seen in patients with acute myeloid leukemia (44.3%), acute lymphoid leukemia (40.5%), and non-Hodgkin lymphoma (36.8%). The non-survivors were significantly older (p<0.001) and had more comorbidities (p<0.05). There were significantly more patients with low lymphocyte percentage (p<0.001), thrombocytopenia (p<0.001), and high CRP (p<0.001) in the non-survived patients. Cardiac comorbidities, (p=0.016), cytotoxic chemotherapy (p=0.024), low lymphocyte percentage (p=0.025), thrombocytopenia (p<0.0001), and high CRP values (p=0.017) were the independent risk factors for the prediction of mortality. Conclusions: In patients with hematologic malignancies, coexistent COVID-19 leads to a higher mortality rate in elderly patients with more comorbidities. Acute myeloid and lymphoid leukemia and non-Hodgkin lymphoma have the highest mortality rates. Cardiac diseases, cytotoxic chemotherapy, lymphopenia, thrombocytopenia, and high CRP are the independent risk factors for mortality in hematologic malignancy patients with COVID-19. Keywords: Covid; Hematologic Malignancy; Cytotoxic chemotherapy. http://mjhid.org/index.php/mjhid/article/view/5054Hematologic malignanciesCOVID-19 virus diseasemortality |
| spellingShingle | İbrahim Halil Açar Sebnem Izmir Güner Muzeyyen Aslaner Ak Mesut Gocer Erman Ozturk Figen Atalay Gulden Sincan Aysun Senturk Yikilmaz Omer Ekinci Idris Ince Emine Gulturk Nazli Demir Ali Dogan Yildiz Ipek Birol Guvenc IMPACT OF COVID-19 ON OUTCOMES OF PATIENTS WITH HEMATOLOGIC MALIGNANCIES: A MULTI-CENTER, RETROSPECTIVE STUDY Mediterranean Journal of Hematology and Infectious Diseases Hematologic malignancies COVID-19 virus disease mortality |
| title | IMPACT OF COVID-19 ON OUTCOMES OF PATIENTS WITH HEMATOLOGIC MALIGNANCIES: A MULTI-CENTER, RETROSPECTIVE STUDY |
| title_full | IMPACT OF COVID-19 ON OUTCOMES OF PATIENTS WITH HEMATOLOGIC MALIGNANCIES: A MULTI-CENTER, RETROSPECTIVE STUDY |
| title_fullStr | IMPACT OF COVID-19 ON OUTCOMES OF PATIENTS WITH HEMATOLOGIC MALIGNANCIES: A MULTI-CENTER, RETROSPECTIVE STUDY |
| title_full_unstemmed | IMPACT OF COVID-19 ON OUTCOMES OF PATIENTS WITH HEMATOLOGIC MALIGNANCIES: A MULTI-CENTER, RETROSPECTIVE STUDY |
| title_short | IMPACT OF COVID-19 ON OUTCOMES OF PATIENTS WITH HEMATOLOGIC MALIGNANCIES: A MULTI-CENTER, RETROSPECTIVE STUDY |
| title_sort | impact of covid 19 on outcomes of patients with hematologic malignancies a multi center retrospective study |
| topic | Hematologic malignancies COVID-19 virus disease mortality |
| url | http://mjhid.org/index.php/mjhid/article/view/5054 |
| work_keys_str_mv | AT ibrahimhalilacar impactofcovid19onoutcomesofpatientswithhematologicmalignanciesamulticenterretrospectivestudy AT sebnemizmirguner impactofcovid19onoutcomesofpatientswithhematologicmalignanciesamulticenterretrospectivestudy AT muzeyyenaslanerak impactofcovid19onoutcomesofpatientswithhematologicmalignanciesamulticenterretrospectivestudy AT mesutgocer impactofcovid19onoutcomesofpatientswithhematologicmalignanciesamulticenterretrospectivestudy AT ermanozturk impactofcovid19onoutcomesofpatientswithhematologicmalignanciesamulticenterretrospectivestudy AT figenatalay impactofcovid19onoutcomesofpatientswithhematologicmalignanciesamulticenterretrospectivestudy AT guldensincan impactofcovid19onoutcomesofpatientswithhematologicmalignanciesamulticenterretrospectivestudy AT aysunsenturkyikilmaz impactofcovid19onoutcomesofpatientswithhematologicmalignanciesamulticenterretrospectivestudy AT omerekinci impactofcovid19onoutcomesofpatientswithhematologicmalignanciesamulticenterretrospectivestudy AT idrisince impactofcovid19onoutcomesofpatientswithhematologicmalignanciesamulticenterretrospectivestudy AT eminegulturk impactofcovid19onoutcomesofpatientswithhematologicmalignanciesamulticenterretrospectivestudy AT nazlidemir impactofcovid19onoutcomesofpatientswithhematologicmalignanciesamulticenterretrospectivestudy AT alidogan impactofcovid19onoutcomesofpatientswithhematologicmalignanciesamulticenterretrospectivestudy AT yildizipek impactofcovid19onoutcomesofpatientswithhematologicmalignanciesamulticenterretrospectivestudy AT birolguvenc impactofcovid19onoutcomesofpatientswithhematologicmalignanciesamulticenterretrospectivestudy |